Rotavirus Prophylaxis Industry Anticipated to Expand at 9.8% CAGR During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Rotavirus Prophylaxis Market Between 2025 And 2029?

The rotavirus prophylaxis market has experienced substantial expansion in recent years. This market is projected to grow from $9.05 billion in 2024 to $9.94 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.8%. Historically, this expansion has been driven by factors such as improved vaccine access and equity, the emergence of new rotavirus strains, increased research and development investments, and enhanced public health preparedness.

The rotavirus prophylaxis market is anticipated to undergo significant expansion in the coming years. It is projected to achieve a valuation of “$14.45 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.8%. The impetus for this growth during the forecast period stems from the burden of gastrointestinal diseases, increasing global presence, ongoing vaccination programs, and rising vaccine confidence. Prominent trends for this period encompass the development of next-generation vaccines, combination vaccines, innovations in vaccine delivery, and collaborative global immunization efforts.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp

What Are The Drivers Pushing New Developments In The Rotavirus Prophylaxis Market?

A rise in the availability of vaccine courses is anticipated to fuel the expansion of the rotavirus prophylaxis market moving ahead. A vaccine course represents a defined quantity of vaccine administered to an individual to establish immunity against a specific illness. This administered vaccine dose activates the immune system, offering substantial defense against rotavirus infection. Such heightened immunity reduces the likelihood of illness and boosts the vaccine’s overall effectiveness. As an illustration, in January 2022, a report from the United Nations International Children’s Emergency Fund (UNICEF), a US-based organization delivering humanitarian and developmental aid to children, indicated that approximately 5.71 million courses of RV1-5 frozen rotavirus vaccine were manufactured in 2022, with forecasts suggesting a rise to 9.31 million courses by 2028. Additionally, 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were produced in 2022, with an expected increase to 6.13 million courses by 2028. Consequently, the growing volume of vaccines will propel the rotavirus prophylaxis market.

What Are The Key Segments In The Rotavirus Prophylaxis Market?

The rotavirus prophylaxismarket covered in this report is segmented –

1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments

2) By Route of Administration: Oral; Parenteral; Other Route of Administrations

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Rotarix: Single Dose; Multi-Dose

2) By Rotavac: Liquid Formulation; Freeze-Dried Formulation

3) By Rotavin-M1: Liquid Formulation; Freeze-Dried Formulation

4) By Oral Rehydration Fluid: Electrolyte Solutions; Glucose-Based Solutions

5) By Other Treatments: Supportive Care; Antidiarrheal Medications

How Are Emerging Market Trends Shaping The Rotavirus Prophylaxis Industry Landscape?

Leading companies within the rotavirus prophylaxis market are actively developing vaccines to meet diverse customer needs. The process for vaccine approvals is rigorous, involving multiple stages of development and thorough testing. These approvals are vital for ensuring that vaccines are both safe and effective in preventing this particular viral illness, especially among infants and young children. For instance, in November 2022, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology firm, announced that the Food and Drug Administration (FDA) had approved an oral-dosing applicator-only presentation (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral), which protects infants from rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4 and G9). This new oral-dosing applicator-only presentation is completely liquid and does not require reconstitution before use. Both the lyophilized and liquid formulations of ROTARIX are administered orally as a two-dose series, contain the same live, human-attenuated rotavirus strain, and are manufactured using comparable techniques.

Who Are The Major Companies Operating In The Rotavirus Prophylaxis Market?

Major companies operating in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report

Which Regional Markets Are Contributing Most To The Rotavirus Prophylaxis Industry Expansion?

North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Rotavirus Prophylaxis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13045&type=smp

Browse Through More Reports Similar to the Global Rotavirus Prophylaxis Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Dtp Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795